|Bid||74.43 x 300|
|Ask||75.45 x 100|
|Day's Range||77.18 - 78.70|
|52 Week Range||73.69 - 89.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 24, 2018|
|Forward Dividend & Yield||2.25 (2.85%)|
|1y Target Est||91.62|
Eli Lilly and Co (NYSE:LLY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
INDIANAPOLIS , Feb. 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 38 th Annual Health Care Conference on Tuesday, March 13, 2018 . Sue Mahony , Ph.D., ...
INDIANAPOLIS, Feb. 20, 2018 /PRNewswire/ --Eli Lilly and Company (LLY) announced today findings from a Lilly-sponsored, quantitative opinion survey, which found among those surveyed, people diagnosed with migraine experienced on average 15.4 completely pain-free days over the previous 30 days. The Migraine Impact Report also highlighted the impact of migraine on a person's day-to-day-life, with respondents noting the symptoms of their migraine prevented them from doing what they wanted to do for one week (6.9 days) over the previous 30 days. The Migraine Impact Report evaluated the physical, social and economic challenges of migraine.
INDIANAPOLIS, Feb. 19, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) announced today that patients with moderate-to-severe genital psoriasis treated with Taltz® (ixekizumab) reported a greater decrease in the impact of their condition on sexual activity compared to placebo after 12 weeks of treatment. "Over the course of their disease, up to 63 percent of psoriasis patients experience genital psoriasis, which can be difficult to treat and can have a significant impact on their sexual health," said Dr. Lotus Mallbris, vice president, immunology platform team leader, product development. In the study, 149 patients with moderate-to-severe genital psoriasis were randomized to receive Taltz (80 mg every two weeks, following a 160-mg starting dose) or placebo.
Because of variability on the clinical trial’s primary endpoint, the company increased the sample size for two ongoing trials. Though it rattled investors, some on Wall Street say it could be a good sign....
Can billion-dollar startups be created from big companies' unused intellectual property? Ex-Walgreens CEO Greg Wasson bets "yes."
Novartis: What Are the Major Growth Drivers for 2018? In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year (or YoY) increase of 53.0% on a constant currency basis and 11.0% growth quarter-over-quarter. This growth was driven by the drug’s rapid uptake in all approved indications and in all geographies, with a focus on the US and Europe.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting LLY. LLY credit default swap spreads are within the middle of their range for the last three years. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
FDA's proposed guidelines come in a week when major disappointments in the field were announced by companies developing drugs to treat Alzheimer's.
- 14 abstracts include data for Taltz in genital psoriasis, baricitinib in atopic dermatitis and mirikizumab in plaque psoriasis - INDIANAPOLIS , Feb. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Lilly's (LLY) psoriasis drug, Taltz, meets all endpoints in a phase III study evaluating it in patients with ankylosing spondylitis.
Merck (MRK) stalls a phase III study evaluating verubecestat for the treatment of prodromal Alzheimer's disease on the recommendation of an external data monitoring committee.
In fiscal 2017, Pfizer’s (PFE) Viagra reported revenues of $1.2 billion, which represented a ~23% decline on a YoY (year-over-year) basis. In 2017, in the US and outside the US (international markets), Viagra generated revenues of $789 million and $416 million, respectively. In 2017, in international markets, Viagra sales remained flat, compared with 2016 while, Viagra witnessed a 31% decline on a YoY basis in the US.